



Integral Diagnostics Limited
ACN 130 832 816

T | +61 3 5339 0704
E | info@idxgroup.com.au

Level 2
288 Victoria Parade
East Melbourne VIC 3002

PO Box 551
East Melbourne VIC 8002

www.integraldiagnostics.com.au

ASX Release

Preliminary FY26 Results and Appointment of New CFO

10 August 2026, Melbourne

Integral Diagnostics Limited (ASX: IDX) today provides an update on its preliminary FY26 full year results and announces the appointment of a new Chief Financial Officer who will join IDX's Managing Director and Chief Executive Officer, Jason Martinez, in supporting the new phase of IDX's leadership.

Preliminary Financial Results for FY26

The preliminary and unaudited financial results for FY26 are presented below. These results reflect a full twelve-month contribution from Capitol Health, compared to ~6 months in the prior year.

- Revenue expected to be approximately \$788m to \$790m up ~25% vs pcp (FY25: \$628.0m)
- Operating EBITDA expected to be approximately \$164m – \$165m up ~30% vs pcp (FY25: \$126.5m)
- Operating EBITDA margin expected to be approximately 20.8% – 21.0% up ~80 basis points vs pcp (FY25: 20.1%). This is in line with IDX's guidance of ~21.0% for the full year FY26.
- Operating NPAT expected to be approximately \$47m – \$48m up ~50% vs pcp (FY25: \$31.6m)
- Diluted Operating EPS expected to be approximately 12.5cps – 12.7cps up ~23% vs pcp (FY25: 10.2cps)

Net Debt to Operating EBITDA has continued to improve to an estimated 2.3x at 30 June 2026 from 2.6x at 30 June 2025 in line with IDX's guidance and evidencing operating discipline and a continued de-gearing trajectory.

Group replacement and growth capex was approximately \$50m for FY26, in line with IDX's guidance of \$45m – \$55m.

The estimates above remain subject to completion of year-end procedures and external audit review. IDX will release its audited FY26 results as scheduled on Tuesday, 25 August 2026.

For personal use only

Appointment of new Chief Financial Officer – Ms Jenny Martin

As part of the transition to Mr Martinez' leadership, IDX is also pleased to announce the appointment of Ms Jenny Martin as its new Chief Financial Officer.

To ensure a smooth transition in financial leadership, Ms Martin joins IDX today as incoming CFO, and will focus on gaining a deep understanding of the business before formally assuming the CFO role on 5 October 2026.

Ms Martin is an experienced healthcare technology executive with a strong track record in finance, operations, commercial leadership and managing complexity and rapid growth over a 25-year career.

Ms Martin was CFO of The Citadel Group Limited (ASX: CGL), a technology and healthcare software company from 2018 to 2020 when the company was taken private, and continued in the CFO role, and assumed the Chief Operating Officer role, until July 2026. Prior to this, she had over 12 years' experience in CFO and senior finance roles in predominantly ASX 200 companies.

Jenny holds a Bachelor of Accounting, is a qualified Chartered Accountant, and is a Graduate of the Australian Institute of Company Directors. She is also a Non-Executive Director and Chair of the Audit and Risk Committee of ASX-listed SenSen Networks Limited (ASX: SNS).

IDX Chair, Toby Hall, said "Jenny's extensive experience in business growth, strategy execution and operational excellence, together with her ability to build strong relationships, greatly impressed the Board. We are excited to welcome her to IDX and look forward to her contribution with Jason to the next stage of IDX's journey."

IDX MD and CEO, Jason Martinez said "I'm delighted to welcome Jenny as our incoming Chief Financial Officer. Her strong financial and healthcare experience will be a valuable addition to our leadership team as we move forward together."

Retirement of current Chief Financial Officer – Mr Craig White

Ms Martin succeeds Mr Craig White who is retiring as CFO after 4½ years in the role, having transformed the finance, risk and legal functions at IDX during that time.

Mr White will hand-over to Ms Martin on 5 October 2026 and remain actively working until 31 October 2026 to support the transition. He will then commence a period of leave before his retirement on 30 April 2027.

Mr Hall continued "On behalf of the Board, I would like to extend my thanks to Craig for his leadership, dedication and significant contributions to IDX. Craig has played an instrumental role, alongside Dr Ian Kadish, in shaping IDX into the organisation it is today. Together, Ian and Craig leave the company with strong foundations and an exceptional team."

FY26 Results Investor Roadshow

As part of IDX's executive leadership transition plan, Mr Martinez and Mr White will present IDX's FY26 audited FY26 results on Tuesday, 25 August 2026 and meet with investors.

For further details contact

Integral Diagnostics

John Merity

Company Secretary

Tel: 0418 817 255

Email: jmerity@idxgroup.com.au

Authorised for lodgement by the Board of Directors of IDX.

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. IDX employs some of Australasia's leading radiologists and diagnostic imaging specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/